Beranda › Leukemia Biphenotypic Akut
Uji klinis Leukemia Biphenotypic Akut yang merekrut di AS
37 studi untuk Leukemia Biphenotypic Akut merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- Seattle, WA15 studi
- Houston, TX11 studi
- New York City, NY10 studi
- Atlanta, GA9 studi
- Durham, NC8 studi
- Chicago, IL7 studi
- Memphis, TN7 studi
- Baldwin Park, CA6 studi
- Aurora, CO6 studi
- Philadelphia, PA6 studi
- Portland, OR6 studi
- Charlotte, NC6 studi
- Dallas, TX6 studi
- Los Angeles, CA6 studi
- Tampa, FL5 studi
- Clifton, NJ5 studi
- Columbus, OH5 studi
- Nashville, TN5 studi
- Minneapolis, MN5 studi
- Fort Worth, TX5 studi
- San Francisco, CA5 studi
- San Diego, CA5 studi
- Cincinnati, OH5 studi
- Greenburgh, NY5 studi
- Boston, MA5 studi
- Mountain View, CA4 studi
- St. Louis, MO4 studi
- Baltimore, MD4 studi
- Akron, OH4 studi
- Orange, CA4 studi
- Jacksonville, FL4 studi
- Indianapolis, IN4 studi
- Miami, FL4 studi
- Denver, CO4 studi
- Greenville, NC4 studi
- Cleveland, OH4 studi
- Ann Arbor, MI4 studi
- Kansas City, MO4 studi
- Louisville, KY4 studi
- Washington, DC4 studi
Berdasarkan negara bagian
- Alabama3 studi
- Alaska3 studi
- Arizona3 studi
- Arkansas3 studi
- California15 studi
- Colorado8 studi
- Connecticut3 studi
- Delaware3 studi
- Distrik Columbia4 studi
- Florida9 studi
- Georgia9 studi
- Hawaii3 studi
- Idaho3 studi
- Illinois7 studi
- Indiana4 studi
- Iowa4 studi
- Kentucky4 studi
- Louisiana4 studi
- Maine3 studi
- Maryland4 studi
- Massachusetts5 studi
- Michigan4 studi
- Minnesota6 studi
- Mississippi3 studi
- Missouri5 studi
- Nebraska4 studi
- Nevada3 studi
- New Hampshire3 studi
- New Jersey6 studi
- New York11 studi
- North Carolina11 studi
- North Dakota3 studi
- Ohio8 studi
- Oklahoma5 studi
- Oregon6 studi
- Pennsylvania6 studi
- Rhode Island3 studi
- South Carolina3 studi
- South Dakota3 studi
- Tennessee10 studi
- Texas13 studi
- Utah3 studi
- Virginia3 studi
- Washington15 studi
- West Virginia3 studi
- Wisconsin5 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Menerima pesertaFase 1
Usia 12 hingga 78 · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT03802695Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Menerima pesertaFase 2
365 Days · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06317662Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT07094750CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT04375631A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Menerima pesertaFase 1/2
30 Days · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT04065399Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT03683433Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
Menerima pesertaFase 1/2Sukarelawan sehat diterima
Hingga usia 50 · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT05322850Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Menerima pesertaFase 3
365 Days – 25 Years · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Menerima pesertaFase 1/2
Hingga usia 22 · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT04726241Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
Menerima pesertaFase 2
Usia 1 hingga 18 · Semua jenis kelamin · Diperbarui 10 Agu 2026 · NCT06390319Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Menerima pesertaFase 1/2
Usia 13 hingga 90 · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT06533579Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
Menerima pesertaFase 1
Usia 1 hingga 30 · Semua jenis kelamin · Diperbarui 3 Agu 2026 · NCT06177067Personalized NK Cell Therapy in CBT
Menerima pesertaFase 2
Usia 15 hingga 80 · Semua jenis kelamin · Diperbarui 30 Jul 2026 · NCT02727803Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Menerima pesertaFase 2
6 Months – 65 Years · Semua jenis kelamin · Diperbarui 22 Jul 2026 · NCT06013423Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Jul 2026 · NCT07046078Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
Menerima pesertaFase 4
Usia 1 hingga 18 · Semua jenis kelamin · Diperbarui 14 Jul 2026 · NCT06289673Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Jul 2026 · NCT07216443Allo HSCT Using RIC and PTCy for Hematological Diseases
Menerima pesertaFase 2
Hingga usia 75 · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT05805605Registry of Older Patients With Cancer
Menerima pesertaStudi observasional
Usia 65 ke atas · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT01137825Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
Menerima pesertaFase 1
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 23 Jun 2026 · NCT06551584A Study of Revumenib and Mezigdomide in People With Leukemia
Menerima pesertaFase 1/2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 22 Jun 2026 · NCT07356154211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Menerima pesertaFase 1/2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 22 Jun 2026 · NCT03128034211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Menerima pesertaFase 1/2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 22 Jun 2026 · NCT03670966Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Jun 2026 · NCT04047641Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Menerima pesertaFase 2Sukarelawan sehat diterima
6 Months · Semua jenis kelamin · Diperbarui 29 Mei 2026 · NCT04195633Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.